Idiopathic pulmonary fibrosis: can cell mediated immunity markers predict clinical outcome?

Meliconi, R; Lalli, E; Borzì, R M; Sturani, C; Galavotti, V; Gunella, G; Miniero, R; Facchini, A; Gasbarrini, G
July 1990
Thorax;Jul1990, Vol. 45 Issue 7, p536
Academic Journal
No abstract available.


Related Articles

  • Lung Remodeling in Interstitial Pneumonia: A New Molecular Target of Pulmonary Fibrosis. Sunohara, Mitsuhiro; Takizawa, Hajime // Current Respiratory Medicine Reviews;2005, Vol. 1 Issue 1, p93 

    It is well demonstrated that inflammatory processes in the interstitium are pivotal as the pathological features of idiopathic interstitial pneumonia (IIP). Standard therapy with corticosteroids may suppress such inflammatory changes, but not result in marked clinical benefits, especially among...

  • Idiopathic Pulmonary Fibrosis.  // Annals of Internal Medicine;Dec76, Vol. 85 Issue 6, p769 

    Focuses on a conference on idiopathic pulmonary fibrosis held by the National Institutes of Health in Bethesda, Maryland on November 13, 1975. Discussion on the clinical aspects of idiopathic pulmonary fibrosis; Information on histologic observations in relation to idiopathic pulmonary...

  • Models of disease behavior in idiopathic pulmonary fibrosis. Johannson, Kerri A.; Ley, Brett; Collard, Harold R. // BMC Medicine;9/24/2015, Vol. 13 Issue 1, p1 

    Idiopathic pulmonary fibrosis is a diffuse parenchymal lung disease of unknown cause. The natural history of disease can vary considerably, making it difficult to predict the clinical trajectory for an individual patient. Accurate prognostication is desirable for clinical management as well as...

  • Clinical use of biomarkers of survival in pulmonary fibrosis. Thomeer, Michiel; Grutters, Jan C.; Wuyts, Wim A.; Willems, Stijn; Demedts, Maurits G. // Respiratory Research;2010, Vol. 11, p89 

    Background: Biologic predictors or biomarkers of survival in pulmonary fibrosis with a worse prognosis, more specifically in idiopathic pulmonary fibrosis would help the clinician in deciding whether or not to treat since treatment carries a potential risk for adverse events. These decisions are...

  • The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis. Nuovo, Gerard J; Hagood, James S; Magro, Cynthia M; Chin, Nena; Kapil, Rubina; Davis, Luke; Marsh, Clay B; Folcik, Virginia A // Modern Pathology;Mar2012, Vol. 25 Issue 3, p416 

    No abstract available.

  • Treatment of Idiopathic Pulmonary Fibrosis with Losartan: A Pilot Project. Couluris, Marisa; Kinder, Brent; Xu, Ping; Gross-King, Margaret; Krischer, Jeffrey; Panos, Ralph // Lung;Oct2012, Vol. 190 Issue 5, p523 

    Background: Idiopathic pulmonary fibrosis is a progressive interstitial lung disease with no current effective therapies. Treatment has focused on antifibrotic agents to stop proliferation of fibroblasts and collagen deposition in the lung. We present the first clinical trial data on the use of...

  • Ambrisentan ineffective in idiopathic pulmonary fibrosis.  // Reactions Weekly;5/11/2013, Issue 1452, p3 

    The article presents clinical trial suggesting the ineffectivity of ambrisentan in idiopathic pulmonary fibrosis treatment.

  • Biomarkers: key to new therapies for IPF. Pinn, Stephen // British Journal of Hospital Medicine (17508460);Jan2014, Vol. 75 Issue 1, p11 

    The article focuses on the need to build better clinical trials and validate biomarkers of progression and treatment response for patients with idiopathic pulmonary fibrosis.

  • Severe pulmonary hypertension in idiopathic nonspecific interstitial pneumonia. Hallowell, Robert W.; Reed, Robert M.; Fraig, Mostafa; Horton, Maureen R.; Girgis, Reda E. // Pulmonary Circulation;2012, Vol. 2 Issue 1, p101 

    Pulmonary hypertension (PH) is a common complication of interstitial lung disease (ILD), particularly in idiopathic pulmonary fibrosis (IPF) and ILD associated with connective tissue disease, where the underlying pathology is often a nonspecific interstitial pneumonia (NSIP) pattern. The degree...

  • CLINICAL TRIAL DIGEST.  // Pulmonary Reviews;Nov2008, Vol. 13 Issue 11, p17 

    A chart is presented that shows the findings from randomized controlled trials, including clinical trials for bronchiolitis, cystic fibrosis, and idiopathic pulmonary fibrosis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics